Nuveen’s Avalo Therapeutics AVTX Stock Holding History

Nuveen’s Portfolio AVTX Stock Details AVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.86M	Buy	+100,633	New	+$1.59M	﹤0.01%	2606
2022 Q2	–	Sell	-141	Closed	-$294K	–	3254
2022 Q1	$294K	Sell	141 -65	-32%	-$163K	﹤0.01%	3126
2021 Q4	$1.01M	Sell	206 -6	-3%	-$36K	﹤0.01%	2860
2021 Q3	$1.37M	Buy	212 +92	+77%	+$746K	﹤0.01%	2847
2021 Q2	$1.13M	Buy	120 +33	+38%	+$276K	﹤0.01%	2965
2021 Q1	$758K	Buy	87 +27	+45%	+$255K	﹤0.01%	2984
2020 Q4	$457K	Buy	60 +1	+2%	+$6.95K	﹤0.01%	3059
2020 Q3	$389K	Buy	59 +5	+9%	+$37.6K	﹤0.01%	3019
2020 Q2	$402K	Buy	54 +29	+116%	+$211K	﹤0.01%	2974
2020 Q1	$176K	Buy	25 +5	+25%	+$52.9K	﹤0.01%	3013
2019 Q4	$310K	Hold	20	–	–	﹤0.01%	3001
2019 Q3	$190K	Hold	20	–	–	﹤0.01%	3126
2019 Q2	$313K	Buy	+20	New	+$303K	﹤0.01%	3114

Other funds holding AVTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Nuveen's AVTX Position: Q2 2026 in Review

Nuveen opened a new position in Avalo Therapeutics (AVTX) in Q2 2026: 100,633 shares worth $1.86M. The stake represents ﹤0.01% of the portfolio and ranks #2606 among its holdings. This is a return to the name: Nuveen previously reported a position in AVTX as recently as Q1 2022.

Nuveen first reported a position in AVTX in Q2 2019 and has held it in 13 quarters since. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

Nuveen held 100,633 shares of Avalo Therapeutics worth $1.86M as of Q2 2026.
Avalo Therapeutics was a new Nuveen position in Q2 2026.
Avalo Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #2606 holding.
Nuveen first reported a position in Avalo Therapeutics in Q2 2019 and has held it in 13 quarters since.
126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.